← Back to Search

Procedure

cTMS for Diabetic Neuropathy

N/A
Waitlist Available
Research Sponsored by McMaster University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
A diagnosis of painful diabetic neuropathy (pDN)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 of intervention, 24 hours post intervention, and 1 week post intervention
Awards & highlights

Study Summary

This trial will assess the effects of cTMS, a non-invasive form of brain stimulation, on diabetic neuropathic pain. Previous research has shown that it can reduce pain, but only works for ~50% of patients. This trial has the potential to make transformative changes in pDN & improve pain relief.

Who is the study for?
This trial is for individuals with painful diabetic neuropathy (pDN), which causes burning or electric shock-like pain in limbs. Participants must have a pDN diagnosis and be able to understand the study. They can't join if they have other chronic pains, use opioids daily, have contraindications to TMS, or psychological issues affecting comprehension.Check my eligibility
What is being tested?
The trial tests a new form of brain stimulation called controlled Transcranial Magnetic Stimulation (cTMS) against a sham procedure over five days. It aims to see if cTMS can reduce pain and improve neurological function in people with pDN.See study design
What are the potential side effects?
While not specified for cTMS, common side effects of similar treatments may include discomfort at the stimulation site, headache, lightheadedness, or temporary hearing changes due to the noise during treatment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with painful diabetic neuropathy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 of intervention, 24 hours post intervention, and 1 week post intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 of intervention, 24 hours post intervention, and 1 week post intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in PROMIS-29 v2.0 Profile
Secondary outcome measures
Change in Pain catastrophizing scale-EN-SF
Change in Patient Perceived Global Index of Change (PGIC)
Change in nerve conduction assessments
+4 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active cTMSActive Control1 Intervention
Controlled Transcranial Magnetic Stimulation (cTMS) will be delivered at 10 Hz, 1500 pulses targeting the hand representation of the left primary motor cortex. cTMS delivery will require ~9 min to complete. This intervention will be performed approximately 5 days per week for 2 weeks. In addition, participants will experience their standard medical care.
Group II: Sham cTMSPlacebo Group1 Intervention
Sham cTMS will be delivered at as a placebo control. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active cTMS. This will be performed approximately 5 days per week for 2 weeks. In addition, participants will experience their standard medical care.

Find a Location

Who is running the clinical trial?

McMaster UniversityLead Sponsor
884 Previous Clinical Trials
2,598,286 Total Patients Enrolled
St. Joseph's Healthcare HamiltonOTHER
196 Previous Clinical Trials
25,514 Total Patients Enrolled

Media Library

Active Controlled Transcranial Magnetic Stimulation (cTMS) (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05937984 — N/A
Diabetic Neuropathy Research Study Groups: Sham cTMS, Active cTMS
Diabetic Neuropathy Clinical Trial 2023: Active Controlled Transcranial Magnetic Stimulation (cTMS) Highlights & Side Effects. Trial Name: NCT05937984 — N/A
Active Controlled Transcranial Magnetic Stimulation (cTMS) (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05937984 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the eligibility criteria for this medical research extend to those aged 35 or under?

"This clinical trial is exclusive to people aged between 20 and 70. There are 74 studies available for those younger than 18, whilst 441 trials cater to individuals older than 65 years old."

Answered by AI

Are researchers currently enrolling participants in this research study?

"The details on clinicaltrials.gov indicate that this medical trial is not presently seeking out participants, with the initial post being published September 1st 2023 and a recent update occurring June 27th 2023. Nonetheless, there are 555 other trials accepting patients at present time."

Answered by AI

Am I eligible to be included in this research endeavor?

"To be eligible for this trial, individuals should have diabetic neuropathy and fit within the age bracket of 20-70. 30 people in total are needed to complete the experiment."

Answered by AI

Who else is applying?

What site did they apply to?
McMaster University
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Treatment for Painful Diabetic Neuropathy
Aimee Nelson 2023. "Treatment for Painful Diabetic Neuropathy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05937984.
All > Neuropathy > Diabetic Neuropathy
~14 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top